Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2003 3
2004 2
2005 5
2006 5
2007 8
2008 7
2009 7
2010 5
2011 8
2012 4
2013 5
2014 3
2015 3
2016 1
2018 1
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Wimmer K, Gampenrieder SP, Bartsch R, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Soelkner L, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162. N Engl J Med. 2021. PMID: 34320285 Clinical Trial.
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer.
Bartsch R, Gampenrieder SP, Rinnerthaler G, Petru E, Egle D, Petzer A, Balic M, Pluschnig U, Sliwa T, Singer C. Bartsch R, et al. Among authors: pluschnig u. Wien Klin Wochenschr. 2022 Jan;134(1-2):63-72. doi: 10.1007/s00508-021-01987-9. Epub 2022 Jan 28. Wien Klin Wochenschr. 2022. PMID: 35089396 Free PMC article.
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.
Rinnerthaler G, Singer C, Petru E, Egle D, Petzer A, Pluschnig U, Gampenrieder SP, Pfeiler G, Gnant M, Grünberger B, Krippl P, Strasser-Weippl K, Suppan C, Brunner C, Pusch R, Sandholzer M, Balic M, Bartsch R. Rinnerthaler G, et al. Among authors: pluschnig u. Wien Klin Wochenschr. 2022 Oct;134(19-20):683-692. doi: 10.1007/s00508-022-02082-3. Epub 2022 Sep 23. Wien Klin Wochenschr. 2022. PMID: 36149495 Free PMC article.
Tissue distribution of epirubicin after severe extravasation in humans.
Nedomansky J, Haslik W, Pluschnig U, Kornauth C, Deutschmann C, Hacker S, Steger GG, Bartsch R, Mader RM. Nedomansky J, et al. Among authors: pluschnig u. Cancer Chemother Pharmacol. 2021 Aug;88(2):203-209. doi: 10.1007/s00280-021-04280-8. Epub 2021 Apr 27. Cancer Chemother Pharmacol. 2021. PMID: 33907881 Free PMC article.
Expression of Her-2 in carcinomas of the esophagus.
Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P. Schoppmann SF, et al. Among authors: pluschnig u. Am J Surg Pathol. 2010 Dec;34(12):1868-73. doi: 10.1097/PAS.0b013e3181f8be17. Am J Surg Pathol. 2010. PMID: 21107094
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.
Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R. Arnold T, et al. Among authors: pluschnig u. Eur J Clin Invest. 2013 Mar;43(3):286-91. doi: 10.1111/eci.12043. Epub 2013 Jan 25. Eur J Clin Invest. 2013. PMID: 23410002
Brain metastases free survival differs between breast cancer subtypes.
Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R. Berghoff A, et al. Among authors: pluschnig u. Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10. Br J Cancer. 2012. PMID: 22233926 Free PMC article.
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: pluschnig u. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
64 results